高级检索
郭刚, 陈楠, 李高峰, 王德光, 张继朋, 陈瑞彬. 培美曲塞联合奈达铂二线治疗肺腺癌临床观察[J]. 实用临床医药杂志, 2011, (19): 105-107. DOI: 10.3969/j.issn.1672-2353.2011.19.038
引用本文: 郭刚, 陈楠, 李高峰, 王德光, 张继朋, 陈瑞彬. 培美曲塞联合奈达铂二线治疗肺腺癌临床观察[J]. 实用临床医药杂志, 2011, (19): 105-107. DOI: 10.3969/j.issn.1672-2353.2011.19.038
shu
GUO Gang, CHEN Nan, LI Gao-feng, WANG De-guang, ZHANG Ji-peng, CHEN Rui-bin. Clinical observation of Pemetrexed combined Nedaplatin as second-line treatment for lung adenocarcinoma[J]. Journal of Clinical Medicine in Practice, 2011, (19): 105-107. DOI: 10.3969/j.issn.1672-2353.2011.19.038
Citation: GUO Gang, CHEN Nan, LI Gao-feng, WANG De-guang, ZHANG Ji-peng, CHEN Rui-bin. Clinical observation of Pemetrexed combined Nedaplatin as second-line treatment for lung adenocarcinoma[J]. Journal of Clinical Medicine in Practice, 2011, (19): 105-107. DOI: 10.3969/j.issn.1672-2353.2011.19.038
shu

培美曲塞联合奈达铂二线治疗肺腺癌临床观察

Clinical observation of Pemetrexed combined Nedaplatin as second-line treatment for lung adenocarcinoma

    摘要
  • 摘要: 目的 评价培美曲塞联合奈达铂二线治疗肺腺癌的疗效及不良反应.方法 收集晚期肺腺癌患者34例,既往接受一线接受化疗失败28例,曾行EGFR-TKI治疗后病情进展6例；给予2个周期以上堵美曲塞(500 mg/m2,d1)联合奈达铂(80 mg/m2,d1)治疗,21 d为1周期.结果 34例患者完全缓解(ca)0例、部分缓解(PR)5例、稳定(SD) 16例、进展(PD) 13例,有效率(RR)为14.7％；中位生存时间10.4月,1年生存率44.1％.结论 培美曲塞联合奈达铂二线治疗肺腺癌疗效好、可改善患者生活质量、毒性反应轻,对于分子靶向药物耐受的患者有一定疗效.

     

    • HTML全文
    • 参考文献(8)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回